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The aim of the work described in this thesis was initially to screen the ethanol extracts of 
eleven Indonesian ginger species (Zingiberaceae family) for anticancer activity. MGF-7 breast and 
HT-29 colon cancer cells were used for the investigations. Extracts of Zingiber aromaticum and 
Boesenbergia pandurata were found to be the most active species, similar to that of Curcuma langa 
which has been shown to possess anticancer activity in vitro and in vivo (Aruna and 
Sivaramakrishnan, 1992; Azuine and Bhide, 1992). These two active species were then further 
investigated. Bioactive compounds from the species were isolated and identified using various 
chromatography procedures and nuclear magnetic resonance (NMR) and their anticancer activities 
were further tested on MGF-7 breast and HT -29 colon cancer cells including cell cycle analysis and 
measurements of apoptosis. The ethanol extracts of these two active species were also investigated 
using the AOM-induced colon cancer model in rats. The antiinflammatory activity of the ethanol 
extract of Z. aromaticum was also investigated using dextran sulfate sodium (DSS) induced ulcerative 
colitis (UG) in rats. 
The inhibitory activity of ethanol extracts of rhizomes of 11 ginger species was initially tested 
against MGF-7 breast and HT-29 colon cancer cells using colorimetric tetrazolium salt (MTT) assay. 
Ethanol extracts of eight species (Amommum cardamomum, C. /onga, C. mangga, C. xanthorrhiza, 
Boesenbergia pandurata, Zingiber aromaticum, Z. officina/e, Z. cassumunar) showed a strong 
inhibitory effect on the growth of the cancer cells with the IG50 concentrations between 10-1 00 _g/ml. 
The ethanol extract of Curcuma aeruginosa was less active (IG5o between 1 00-120 _g/ml) and 
extracts of Kaempferia ga/anga/ and K. rotunda had no effect on the growth of either cell lines at 
concentrations up to 250 _g/ml. Ethanol extract of C. longa was used as a comparison since 
curcumin, an active compound isolated from this species, has had demonstrated its anticancer 
activity in vitro, in vivo and is currently undergoing clinical trial against colon cancer (Greenwald, et aI., 
2001; Sharma et aI., 2001). Extracts of Z. aromaticum and B. pandurata had very strong inhibitory 
activity similar to the extract of C. /onga. Curcumin was not detectable in either Z. aromaticum or B. 
pandurata. The ethanol extracts of the active species were not toxic on human skin fibroblast cells (SF 
3169). 
The ethanol extracts of Z. aromaticum and B. pandurata were further fractionated using two 
different solvents by reversed phase preparative HPLC. Fraction A was eluted with a mobile phase 
containing 5% vlv aqueous methanol containing 0.025% vlv tri'fluoroacetic acid (TFA) and fraction B 
was eluted with 100% methanol. The inhibitory activity of fractions was then investigated against HT-
29 colon cancer cells and assayed using the MTT assay. Zerumbone, a sesquiterpenoid compound 
was isolated from fraction B of the extract of Z. aromaticum and a chalcone derivative, panduratin A 
was isolated from fraction B of the extract of B. pandurata. Curcumin was in fraction A of extract of C. 
longa. 
The anticancer activity of zerumbone and panduratin A was investigated using MCF-7 breast. 
HT-29 and CaCo-2 colon cancer cells. The inhibitory activity of the active compounds was assessed 
using the MTT assay. The ICso of zerumbone in each of the cell lines was about 10 IJM and of 
curcumin on HT-29 cells was 251JM. The IC50 of panduratin A in HT-29 cells was 16 IJM and in MCF-
7 cells was 9 IJM. Zerumbone and panduratin A showed antiproliferative effects by alteration of the 
DNA distribution in the cell cycle and induction of apoptosis. HT-29 cells treated with zerumbone at 
concentrations of 10 - 25 IJM or panduratin A at concentrations of 9 - 65 IJM for 24 h were stained 
with propidium iodide (PI) to determine cell cycle distribution and analysed using FACScan flow 
cytometry. The proportion of cells in the S phase was reduced from 18.7% in untreated cells to 10.2% 
in HT-29 cells after treatment with zerumbone at 10 IJM to 3.1% at 25 IJM. Cells in the G2 phase 
increased from 18.5% at 10 IJM to 40% at a concentration of 25 IJM. Panduratin A increased the 
proportion of cells in the GO/G1 phase from 33% of untreated cells to 71% after treatment with 65 IJM 
for 24 h. Panduratin A slightly reduced the proportion of cells in S phase and cells in G2/M phase also 
decreased from 36,8% in untreated cells to 15.4% at 65 rM. Apoptosis was determined using double 
labelled (Annexin-V-Fluos and PI) and then evaluated using FACScan Flow Cytometry. Morphological 
features of apoptosis were also examined using DiffQuick stain and fluorescent Hoechst 3355 and 
4,6-diamino-2-phenylindole (DAPI). Zerumbone induced apoptosis in HT-29 cells in a dose dependent 
rnanner, At 48 h, 2% of cells treated with 10 rM of zerumbone underwent apoptosis, which increased 
to 8% when treated with 50 rM, Panduratin A at 28 rM increased the number of cells undergoing 
apoptosis from 2,2% to 16.7% when treated with a concentration of 65 rM. The ethanolic extracts of 
Z. aromaticum and B. pandurata were also investigated using the azoxymethane (AOM) induced 
aberrant crypt foci (ACF) model of colon cancer in rats in a short and long term study. Ethanolic 
extracts of C. tonga and curcumin were used as comparison. The basal diet used throughout all 
animal studies in this thesis was a semi-purified AIN-93 G diet (Reeves et aI., 1993). ACF were 
induced by two doses (15 mg/kg BW) subcutaneously of AOM one week apart and ACF were 
visualised in the formalin fixed colon using methylene blue stain. The ACF study was run over a short 
(5 weeks) and long (13 weeks) experiments. Diets containing ethanol extracts prepared from the 
equivalent of 2% (w/w) dried rhizome of Z. aromaticum, B. pandurate or C. tonga in a short term study 
did not affect the formation of ACF in rats compared to those in the control diet group. The ACF 
formation in a short term study was dominated by small numbers of aberrant crypts (1 or 2) per focus. 
It is suggested that large ACF (4 or more ACs/focus) are better predictors of colon cancer (Uchida et 
aI., 1997; Jenab et aI., 2001). Diets containing ethanol extracts of the equivalent of 4% by weight of 
dried rhizomes of Z. aromaticum, B. pandurata, C. longa were investigated over 13 week study, Total 
ACF were significantly reduced by Z. aromaticum extract (0.34%) in the diet (down 21%, p<0.05) 
relative to rats fed the control diet. A similar reduction was observed with C, longa extract (0.86%) in 
the diet (down 24%, p<0.01) and with 2000 ppm curcumin. There was no significant different in small 
ACFs (1-2 ACs/ focus) between dietary treatments. The number of foci containing 3-4 ACs/focus was 
significantly reduced (35%, p<0,001) in animals fed the Z. aromaticum extract and 34% (p<0.001) of 
animals fed the C. tonga extract. The total number of ACF containing 5 or more ACs per focus of 
animals fed 0.34% Z. aromaticum extract was 41 % lower than control (p<0.05) and for 0.86 % C. 
tonga extract was 22% (not significant). A diet containing extract (0.56%) of B. pandurata did not 
significantly affect the formation of ACF compared to the control AIN group. The concentration of 
zerumbone in the Z.aromaticum extract diet was assayed at 300 ppm, and of curcumin in the C. tonga 
extract diet was also 300 ppm. The concentration of panduratin A was not assayed in the diet due to 
late identification of the active compound. 
The antiinflammatory activity of ethanol extract of Z. aromaticum was investigated using 
dextran sulfate sodium (DSS) induced ulcerative colitis in rats. Sulfasalazine, a widely used 
compound to treat inflammatory bowel disease (IBD) in humans was used as the positive control. 
Diets containing ethanol extracts (0.34% and 0.68%) prepared from the equivalent of 4% and 8% by 
weight of dried rhizomes of Z. aromaticum were given to the animals throughout the experiment. On 
day three, rats were given 2% DSS in drinking water for 5 d and then just water for 3 d and then were 
killed. During the DSS treatment rats were maintained in metabolic cages, body weight, food and fluid 
intake and clinical symptoms such as consistency of stools and blood in faeces were recorded daily. 
There was slight but not significant reduction in the body weight of rats fed 0.68% extract of Z. 
aromaticum in the diet due to reduced food consumption. The extract of Z. aromaticum (0.34%) and 
sulfasalazine suppressed clinical signs of ulcerative colitis. Eleven percent of the controls were 
hemoccult positive on day 2 after DSS administration, which progressed further by day three with 67% 
being hemoccult positive and 100 % on day five. By comparison, blood appeared on day 3 of rats 
treated with diet containing 0.34% and 0.68% extract of Z. aromaticum and 0.05% sulfasalazine, and 
only 33%, 67% and 22%, of rats being hemoccult positive on day 5 respectively. The disease activity 
index (DAI) of rats fed diet containing 0.34% extract of Z. aromaticum was about 0.4 and similar to 
those which were fed with diet containing sulfasalazine. The DAI of untreated rats was 1.4. The crypt 
score of rats fed the extract of Z. aromaticum was slightly reduced but it was not significantly different 
from those of untreated rats. Other histological scores were not significantly different between dietary 
treatments. Extract of Z. aromaticum significantly decreased the content of PGE-2 in colon tissue 
compared to that of untreated animals. There was a reduction of TX8-2 content in colonic tissue of 
rats fed with extracts of Z. aromaticum but this was not significant. The activity of myeloperoxidase 
(MPO) activity in the colonic tissue of rats fed with sulfasalazine was significantly lower than that of 
the untreated controls and those which fed with extracts of Z. aromaticum. 
The results from the studies performed in this thesis showed that extract of Z. aromaticum 
which contains an active sesquiterpenoid zerumbone have anticancer and antiinflammatory activity 
suggesting that the extract may have benefits as a chernopreventative agent. However further studies 
are needed to elucidate their other pharmacological actions. Panduratin A showed potential 
anticancer activity in cell culture in vitro. However an extract of B. pandurata did not have effect on the 
AOM-induced colon cancer model. Different cancer models such as breast and prostate cancer could 
be used to further investigate the anticancer activity of extract of B. pandurata and panduratin A and 
to elucidate their mechanism. 
